2019 China International Biopharma4.0 Summit

Background

Deep integration of next-generation ICT technologies and manufacturing industry is driving a round of industrial transformation, creating new manufacturing methodologies, industrial forms, business modes and economic growth. All countries are encouraging innovation in science and technology. Following Germany’s Industry 4.0 announcement, China released Made in China 2025, a national strategy to accelerate the transformation and upgrading of manufacturing industry which is led by smart equipment, smart factory and smart manufacturing based on cyber-physical System (CPS).

As one of the 10 key areas described in Made in China 2025, “biopharma and high-performance medical devices” is presented with tremendous challenges and opportunities in innovative development. It’s estimated that China’s medical industry will hit 3.8786 trillion RMB in revenue in 2018, 16.5% higher than last year. The drug market’s revenue will hit 1.7407trillion RMB, 8% higher than 2017. By 2020, the revenue of key businesses in medical industry will grow at medium-high annual rates of over 10%.

Based on the successful previous experience, Biopharma 4.0 Summit 2018 will provide an opportunity to discuss the most concerning policies and regulations, regulations on the use of SUS, the latest progress in technologies, future trends, and hot business mode innovations, with all conversations settled in the background of China’s biopharma industry. The summit will also provide a unique opportunity to communicate with government officials, CMO, CRO biopharma companies, pharmaceutical device providers, software and logistics solutions providers, industry leaders and experts on international projects.

400+

Industry Leaders

100+

Global Renowned Pharmaceutical Companies

30+

Speakers

50+

Media Partners

Agenda Download

Summit highlights:

Main session

Trends in Pharma 4.0 standards and the development of public industrial clouds
Application of AI and Big Data technologies in corporate decision-making
Established pharma group from German sharing its practices in biopharma customization
Pharmaceutical supply chain management enabled by Blockchain
Develop a comprehensive supply chain system integrating warehouse technologies and logistics management
Application of knowledge management, machine learningand Big Data in Industry 4.0

(Session A) Biopharma Single-use System and Smart Continuous Manufacturing:

Application of international pharmaceutical SUS and technical guidance
Industry 4.0 and biopharma continuous manufacturing
Concept of global single-use and key elements of reconfigurable module-based plant
Traditional stainless steel equipment vs. SUS on cost and efficiency
Study on SUS leachable and extractable and localized verification service
Improve biopharma process and QC with AI, integration data, virtual simulation
DoE strategy of QbD

(Session B) Latest OutsourcingMode and Biopharma Development

Discussion about the business mode of contract manufacturing in MAH system
What key measures should pharmaceutical companies take to improve their connection with external supply chain?
Case study: pharmaceutical companies’ contract transfer on expiration and risk management in the entire CDMO life cycle
New Drug Delivery Strategy (DDS)
How to apply AI in new drug development?
Overview of hot targets including McAb, BSAB, ADC, and PD-1
Analysis and clinical challenges of biosimilars development

Who Will Attend?

Authorities and associations
- United States Pharmacopeia
- Shanghai Food and Drug Administration
- China Medicinal Biotech Association
- Ministry of Industry and Information Technology
- SADIE
Industry leaders
- GSK
- Wuxi AppTec
- CASI Cloud
- XiAn Janssen
- Pfizer
- Biogen
- Sanofi
- Nanjing Levena Biophama
- Shanghai RAAS
- Takeda Pharmaceutical
- IBM
- Google

Industry 4.0 Series Events